Compare Amphastar Pharmaceuticals Inc (AMPH) vs iShares 3 7 Year Treasury Bond ETF (IEI) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

IEI (iShares 3-7 Year Treasury Bond ETF) trades at $116.77, down slightly by 0.06% amid broader market volatility. The technical picture remains bearish with moving averages signaling continued pressure, though oscillators show neutral momentum. Recent dividend payments of $0.36-$0.37 highlight the fund's income generation, while bond market uncertainty persists with mixed signals on Federal Reserve policy direction.

The outlook for IEI remains cautious as Treasury yields face upward pressure from inflation concerns and potential Fed rate hikes. While the ETF offers lower volatility than corporate bonds, competition from higher-yielding alternatives like Vanguard's bond ETFs presents headwinds. Key risks include interest rate sensitivity and shifting investor preferences toward higher-yield fixed income options.